Profound Medical Corp.
$7.15
▼
-1.53%
2026-04-21 08:57:00
www.profoundmedical.com
NCM: PROF
Explore Profound Medical Corp. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$331 M
Current Price
$7.15
52W High / Low
$12.4 / $5.23
Stock P/E
—
Book Value
$1.83
Dividend Yield
—
ROCE
-57.78%
ROE
-67.11%
Face Value
—
EPS
$-1.41
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
162
Beta
0.47
Debt / Equity
7.09
Current Ratio
12.53
Quick Ratio
11.17
Forward P/E
-7.59
Price / Sales
13.41
Enterprise Value
$160.94 M
EV / EBITDA
-3.96
EV / Revenue
10
Rating
None
Target Price
$11.9
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Penumbra, Inc. | $333.46 | 73.7 | $13.1 B | — | 11.52% | 13.78% | $362.41 / $221.26 | $36.39 |
| 2. | Biomerica, Inc. | $2.18 | — | $6.74 M | — | -122.16% | -84.3% | $4.6 / $1.87 | $1.5 |
| 3. | Bluejay Diagnostics, Inc. | $1.97 | — | $1.94 M | — | -115.88% | -1.17% | $16.68 / $1.65 | $9.88 |
| 4. | InfuSystem Holdings, Inc. | $10.79 | 32.21 | $213.43 M | — | 14.83% | 11.54% | $11.04 / $4.66 | $2.84 |
| 5. | NovoCure Limited | $12.67 | — | $1.44 B | — | -26.47% | -38.89% | $20.06 / $9.82 | $3.03 |
| 6. | Rapid Micro Biosystems, Inc. | $2.25 | — | $103.66 M | — | -84.08% | -86.82% | $4.94 / $2.01 | $0.75 |
| 7. | CeriBell, Inc. | $21.13 | — | $797.62 M | — | -33.07% | -30.83% | $24.33 / $10.85 | $4.14 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 5.98 M | 5.29 M | 2.21 M | 2.62 M | 3.71 M | — |
| Operating Profit | -7.37 M | -8.91 M | -13.81 M | -11.17 M | -8.76 M | — |
| Net Profit | -8.18 M | -7.98 M | -15.7 M | -10.72 M | -5.33 M | — |
| EPS in Rs | -0.23 | -0.22 | -0.43 | -0.3 | -0.15 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 16.1 M | 10.68 M | 7.2 M | 6.68 M |
| Operating Profit | -41.25 M | -33.06 M | -28.65 M | -29.6 M |
| Net Profit | -42.57 M | -27.82 M | -28.32 M | -28.67 M |
| EPS in Rs | -1.17 | -0.77 | -0.78 | -0.79 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 77.47 M | 70.23 M | 43.96 M | 64.42 M |
| Total Liabilities | 11.04 M | 9.81 M | 12.73 M | 12.42 M |
| Equity | 66.43 M | 60.42 M | 31.22 M | 52 M |
| Current Assets | 76.09 M | 69.06 M | 41.9 M | 62.02 M |
| Current Liabilities | 6.08 M | 6.57 M | 6.37 M | 4.18 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -38.21 M | -23.45 M | -22.61 M | -25.8 M |
| Investing CF | -0.24 M | 0 M | — | 0 M |
| Financing CF | 41.14 M | 54.7 M | 1.76 M | 7.03 M |
| Free CF | -38.45 M | -23.45 M | -22.61 M | -25.8 M |
| Capex | -0.24 M | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 48.35% | 7.75% | — | — |
| Earnings Growth % | 1.79% | 1.21% | — | — |
| Profit Margin % | -260.45% | -393.43% | -429.11% | — |
| Operating Margin % | -309.57% | -397.99% | -443.08% | — |
| Gross Margin % | 65.89% | 59.9% | 45.22% | — |
| EBITDA Margin % | -300.81% | -385.08% | -398.2% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.